Skip to main content

Ocrevus Zunovo News

FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

South San Francisco, CA – September 13, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has...

FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS

THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Multiple Sclerosis

Ocrevus Zunovo patient information at Drugs.com